Want to see SI full AI Analyst Report?
Top Page
Shoulder Innovations, Inc.
(NYSE:SI)
Select Model
Select Model
Rating:49Neutral
Price Target:
$18.50
▼(-10.37% Downside)
Action:Reiterated
Date:10/09/26
The score is held down primarily by worsening losses and accelerating cash burn despite strong revenue growth and high gross margins. Technical indicators are mixed and do not clearly confirm a sustained uptrend, while valuation is constrained by negative earnings. Recent product and commercial leadership updates are constructive but secondary to the current profitability and cash flow pressures.
Positive Factors
Revenue Growth and Gross Margin
Rapid revenue growth combined with consistently high gross margins indicates strong demand and attractive underlying unit economics. If maintained, this combination can support reinvestment in commercial expansion and product development while providing a foundation for eventual operating leverage.
Negative Factors
Accelerating Cash Burn
Increasingly negative operating and free cash flow shows that the business is not yet self-funding despite its revenue growth. Continued cash consumption can constrain investment choices and raise the need for additional financing, particularly if the company’s expansion takes longer to generate profits.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Gross Margin
Rapid revenue growth combined with consistently high gross margins indicates strong demand and attractive underlying unit economics. If maintained, this combination can support reinvestment in commercial expansion and product development while providing a foundation for eventual operating leverage.
Read all positive factors
Shoulder Innovations, Inc. (SI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$377.45M
Dividend YieldN/A
Average Volume (3M)120.34K
Price to Earnings (P/E)―
Beta (1Y)-0.52
Revenue Growth60.90%
EPS Growth-7.99%
CountryUS
Employees74
SectorGeneral
Sector StrengthN/A
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-1.71
Shares Outstanding20,818,956
10 Day Avg. Volume140,118
30 Day Avg. Volume120,344
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)2.10
Price to Sales (P/S)6.23
P/FCF Ratio-8.19
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue5.60
Enterprise Value/Gross Profit7.24
Enterprise Value/Ebitda-10.55
Forecast
1Y Price Target
$26.33Price Target Upside27.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.88
Revenue Forecast (FY)$68.42M
Shoulder Innovations, Inc. Business Overview & Revenue Model
Company Description
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI....
How the Company Makes Money
SI primarily makes money by selling shoulder arthroplasty products (implant systems and related surgical instruments/ancillary components) to healthcare providers (e.g., hospitals and ambulatory surgery centers) that perform shoulder replacement p...
Shoulder Innovations, Inc. Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Positive
The call presented a strong operating and commercial momentum: sizable revenue and volume growth, improving gross margins, accelerating surgeon adoption and meaningful product and technology milestones (I-135 full launch, N22 limited release, >500 patients in registry, and a progressing robotic partnership). These positives were offset by increased operating expenses and larger net and adjusted EBITDA losses as the company invests to scale, a Q1 cash burn driven by inventory and working capital, and some seasonality and ASP/mix variability risk embedded in the updated guidance. Overall, management expressed high conviction in the trajectory and raised full-year guidance while noting near-term investment-related impacts.Positive Updates
Strong Top-Line Growth
Net revenue of $16.7M in Q1 2026, up 65% year-over-year and 16% sequentially, driven by new surgeon adoption, increased utilization and higher ASPs.
Negative Updates
Widening Operating Losses
Net loss increased to $8.4M in Q1 2026 from $4.7M a year earlier; adjusted EBITDA loss rose to $7.0M from $3.5M, primarily driven by higher SG&A and R&D investments.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Growth
Net revenue of $16.7M in Q1 2026, up 65% year-over-year and 16% sequentially, driven by new surgeon adoption, increased utilization and higher ASPs.
Read all positive updates
Company Guidance
Management raised full‑year 2026 net revenue guidance to $65–68 million (growth of 37%–44% vs. 2025; prior range $62–65M or 31%–37%) after a strong Q1: net revenue $16.7M (+65% YoY, +16% sequential), total implant volume 2,184 units (+51% YoY) and gross margin 77.7% (vs. 76.9% a year ago). Q1 operating metrics included SG&A $18.2M (vs. $10.5M prior year) with variable selling expense down from 128% of revenue in Q3 2025 to 109% in Q1 2026, R&D $3.8M (vs. $1.6M), net loss $8.4M, adjusted EBITDA loss $7.0M, and cash & equivalents $108.5M at 3/31/26. Guidance assumes similar gross margins for the balance of 2026 (subject to quarter‑to‑quarter product‑mix and ASP variability), typical seasonality (lighter Q3, step‑up in Q4), a modest rise in SG&A as a percent of revenue in Q2–Q3 to fund greenfield expansion before declining in Q4, and R&D as a percent of revenue moderating late in the year; management also noted increased inventory/asset purchases in H1 but expects significantly lower cash burn starting in Q2 and believes current cash can support the path to cash‑flow breakeven.Shoulder Innovations, Inc. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
66
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 60.05M | 47.32M | 31.62M | 19.27M |
| Gross Profit | 46.45M | 36.20M | 24.34M | 15.27M |
| EBITDA | -31.89M | -37.08M | -12.11M | -10.25M |
| Net Income | -35.03M | -40.36M | -15.62M | -12.65M |
Balance Sheet | ||||
| Total Assets | 152.01M | 169.91M | 43.08M | 54.29M |
| Cash, Cash Equivalents and Short-Term Investments | 98.99M | 124.31M | 15.04M | 32.81M |
| Total Debt | 14.85M | 15.02M | 14.73M | 14.46M |
| Total Liabilities | 27.68M | 29.16M | 97.78M | 94.03M |
| Stockholders Equity | 124.33M | 140.75M | -54.70M | -39.74M |
Cash Flow | ||||
| Free Cash Flow | -47.08M | -36.02M | -18.16M | -15.89M |
| Operating Cash Flow | -37.09M | -28.61M | -14.14M | -13.14M |
| Investing Cash Flow | -72.40M | -95.60M | 13.96M | -28.97M |
| Financing Cash Flow | 106.89M | 144.96M | 66.00K | 44.73M |
Shoulder Innovations, Inc. Technical Analysis
Negative
20.64
Price Trends
19.89
Negative
19.37
Negative
16.68
Positive
Market Momentum
-0.32
Negative
43.49
Neutral
38.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SI, the sentiment is Negative. The current price of 20.64 is above the 20-day moving average (MA) of 18.18, above the 50-day MA of 19.89, and above the 200-day MA of 16.68, indicating a neutral trend. The MACD of -0.32 indicates Negative momentum. The RSI at 43.49 is Neutral, neither overbought nor oversold. The STOCH value of 38.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SI.
Shoulder Innovations, Inc. Risk Analysis
Shoulder Innovations, Inc. disclosed 79 risk factors in its most recent earnings report. Shoulder Innovations, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Shoulder Innovations, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $1.85B | 27.88 | 16.42% | 1.18% | 11.85% | 38.09% | |
71 Outperform | $5.21B | 35.60 | 9.07% | ― | 10.51% | 20.67% | |
65 Neutral | $4.01B | 132.83 | 1.41% | ― | -8.84% | ― | |
62 Neutral | $1.65B | -14.79 | -818.99% | ― | 19.47% | 36.87% | |
58 Neutral | $2.05B | 83.57 | 6.91% | ― | 22.95% | 228.76% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | $377.45M | -10.62 | -25.67% | ― | 60.90% | -7.99% |
* General Sector Average
SI
Shoulder Innovations, Inc.
18.13
5.97
49.10%
VCEL
Vericel
40.10
6.61
19.74%
ATEC
Alphatec Holdings
10.67
-2.57
-19.41%
ICUI
ICU Medical
160.32
44.06
37.90%
LMAT
Lemaitre Vascular
80.69
-3.77
-4.46%
MMSI
Merit Medical Systems
87.21
7.78
9.79%
Shoulder Innovations, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Shoulder Innovations Launches Next-Generation InSet Go Glenoid Implant
Positive
Oct 8, 2026
Shoulder Innovations, Inc., a commercial-stage medical technology firm specializing in shoulder arthroplasty, develops advanced implant systems and an integrated ecosystem spanning preoperative planning, implant design and procedural efficiency. I...
Business Operations and StrategyExecutive/Board Changes
Shoulder Innovations Promotes Jon Osborne to Commercial Chief
Positive
Aug 10, 2026
On August 10, 2026, Shoulder Innovations, Inc. announced that it had promoted Jon Osborne to Chief Commercial Officer, effective August 6, 2026, expanding his responsibilities to lead all aspects of the company’s commercial organization. Osb...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.